CorMedix Inc (CRMD)

[dshade]

"we believe we have the resources to fund the significant cost of winding down the LOCK-IT-100 study and to prepare for and hold our planned meeting with the FDA with respect to Neutrolin proposed development plan without additional financing.

The extents of our future financing needs will become clearer, once we reach agreement with the FDA regarding the final development path to Neutrolin. But depending upon the ultimate disposition of the negotiations with our CRO, we maybe able to continue operations to year-end or beyond without the need to raise additional funds. We will consider opportunistic financing earlier to ensure sufficient funds for our planned operations. Yes, we believe such a transaction would be in our shareholders best interest. We will provide an update on our CRO negotiations as soon as possible."